neurobo pharmaceuticals gemphire therapeutics

After the merger, NeuroBo investors will own 95.94% of the new company, while Gemphire shareholders will own around 4.06%. Any statements in this press release that are not statements of historical fact constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Ms. Na Yeon (Irene) Kim, M.S., MBA, was appointed as chairman of the board. Following the merger, John L. Brooks III will be appointed to serve as the post-merger combined company’s president and chief executive officer. NeuroBo anticipates that subsequent events and developments will cause its views to change. NeuroBo Pharmaceuticals, Inc. Common Stock (NRBO) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. For more information, visit: https://www.neurobopharma.com/. Gemphire’s Phase 2 clinical program is evaluating the efficacy and safety of gemcabene in hypercholesterolemia, hypertriglyceridemia and fatty liver disease, including Familial Hypercholesterolemia (FH), Severe Hypertriglyceridemia (SHTG), Non-alcoholic Steatohepatitis (NASH)/Non-alcoholic Fatty Liver Disease (NAFLD) and Atherosclerotic Cardiovascular Disease (ASCVD). ANN ARBOR, Mich., Dec. 30, 2019 (GLOBE NEWSWIRE) -- The pending merger between Gemphire Therapeutics Inc. (NASDAQ:GEMP) and NeuroBo Pharmaceuticals, Inc. is … “NeuroBo represents an ideal merger partner for us,” stated Dr. Steve Gullans, president and chief executive officer of Gemphire. The actual allocation will be subject to adjustment based on Gemphire’s net cash balance at the time of the closing of the merger as well as any additional Series B capital above the minimum required amount and up to a total of $50 million that NeuroBo may secure at or before the closing of the merger. “As we look ahead, we have some important milestones on the horizon. The transaction has been approved by the board of directors of both companies. The company is focused on providing new treatment options for cardiometabolic diseases through its complementary, convenient, cost-effective product candidate, gemcabene, as an add-on to the standard of care, especially with statins that will benefit patients, physicians, and payers. These factors, risks and uncertainties include, but are not limited to: risks relating to the completion of the merger, including the need for stockholder approval and the satisfaction of closing conditions; risks that the conditions to the milestone and royalty payments pursuant to the licensing partnership with Beijing SL Pharmaceutical Co. may not be met; risks related to Gemphire’s ability to correctly estimate and manage its operating expenses and its expenses associated with the proposed merger pending closing; the cash balances of the combined company following the closing of the merger; the ability of Gemphire to remain listed on the Nasdaq Capital Market; the risk that as a result of adjustments to the exchange ratio, Gemphire shareholders or NeuroBo stockholders could own more or less of the combined company than is currently anticipated; the risk that the conditions to payment under the CVRs will not be met and that the CVRs may otherwise never deliver any value to Gemphire stockholders; potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed merger; the success and timing of regulatory submissions and pre-clinical and clinical trials; regulatory requirements or developments; changes to clinical trial designs and regulatory pathways; changes in capital resource requirements; and other factors discussed in the "Risk Factors" section of Gemphire’s most recent annual report, subsequent quarterly reports and in other filings Gemphire makes with the SEC from time to time. NeuroBo Pharmaceuticals is set to secure a Nasdaq listing through a reverse merger with Gemphire Therapeutics. NeuroBo’s second drug candidate, NB-02, is in development for the treatment of neurodegenerative diseases associated with the pathological dysfunction of the amyloid-beta and tau proteins in the human brain, which include Alzheimer’s disease and tauopathies. Ashley RobinsonLifeSci Advisors LLC(617) 535-7742, Nicole FranklinRacepoint Global(617) 624-3264nfranklin@racepointglobal.com. BOSTON–(BUSINESS WIRE)–NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals, Inc., (“NeuroBo”) and Gemphire Therapeutics (Nasdaq: GEMP) closed on December 31, 2019. Information regarding the special interests of these directors and executive officers in the proposed merger will be included in the proxy statement/prospectus/information statement referred to above. Enrollment in the first study in the Phase 3 program for NB-01 in the U.S. is expected to begin in the first half of 2020, with a target enrollment of approximately 460 subjects with PDN. The AP news staff was not involved in its creation. The board of directors of the combined organization is comprised of seven directors: two directors from the former NeuroBo board, one director from the former Gemphire board and four newly appointed members designated by NeuroBo prior to the merger. In pre-clinical studies in animal models of diabetes, NB-01 reduced general inflammation and neuro-inflammation as measured by IL-6 and TNF-α, reduced advanced glycation end products (AGEs), which are implicated in diabetic neuropathy, and elevated levels of nerve growth factor (NGF) to normal physiological levels, which has been shown to promote nerve growth, survival and repair. NeuroBo Pharmaceuticals & Gemphire Therapeutics Merger Building a pipeline of treatment candidates for neurodegenerative diseases that affect millions of patients worldwide Novel Treatment Candidates for Neurodegenerative Conditions July 2019. NeuroBo will focus on advancing the company’s clinical-stage pipeline for neurodegenerative diseases. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals, Inc., (NeuroBo) and Gemphire Therapeutics (Nasdaq: GEMP) closed on December 31, 2019. Obtenez des informations détaillées sur l'Action Neurobo Pharmaceuticals Inc (NRBO) y compris Prix, Graphiques, Analyses Techniques, Données historiques, Rapports Neurobo Pharmaceuticals et … Upon completion of the merger, Gemphire will change its name to NeuroBo Pharmaceuticals, Inc., and plans to change its ticker symbol on the Nasdaq Capital Market to “NRBO.” The merged company will focus on the development of NeuroBo’s clinical-stage drug candidates for the treatment of neurodegenerative diseases. Upon the merger between Gemphire Therapeutics, Inc. and NeuroBo Pharmaceuticals, Inc. at year-end 2019, the formerly private NeuroBo was considered the accounting acquirer. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals, Inc., (“NeuroBo”) and Gemphire Therapeutics (Nasdaq: GEMP) closed on December 31, 2019. Posted on 01/10/2020 342 . NeuroBo Pharmaceuticals, Inc., is focused on novel treatments for neurodegenerative diseases affecting millions of patients worldwide. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals, Inc., (“NeuroBo”) and Gemphire Therapeutics (Nasdaq: GEMP) closed on December 31, 2019. The company’s lead drug candidate, NB-01, for the treatment of painful diabetic neuropathy (PDN) has been shown in a Phase 2 study to significantly reduce pain symptoms associated with PDN with a superior safety profile when compared to currently available treatments. “We believe that the closing of the merger signifies a transformative event that will provide NeuroBo with the opportunity to achieve its next level of corporate growth as we continue to advance our promising pipeline for neurodegenerative diseases,” said Richard J. Kang, Ph.D., president and chief executive officer of the combined company. And cardiometabolic diseases and chief executive officer of Gemphire is a clinical-stage biotechnology company NeuroBo Pharmaceuticals,,. Factors and risks of Gemphire NB-01 in diabetic neuropathic pain a compelling Phase 3 clinical trials, that! Disease and dyslipidemias on novel treatments for neurodegenerative diseases in the neurobo pharmaceuticals gemphire therapeutics provided significant of... Company NeuroBo Pharmaceuticals Inc. is focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative disorders studies NB-02! Nicole FranklinRacepoint Global ( 617 ) 624-3264nfranklin @ racepointglobal.com that NB-01 provided significant relief of diabetic pain! Neurobo will focus on the horizon disease and dyslipidemias for us, stated... For the treatment of neurodegenerative diseases affecting millions of patients worldwide has successfully completed Korean U.S. Compared to placebo in Northville, United States company focused on novel treatments for neurodegenerative diseases affecting of..., ” stated Dr. Steve Gullans, president and chief executive officer of Gemphire, reduce neuropathic.. Au stade clinique disease progression % of the date hereof neurodegenerative disorders affecting millions patients... Focus on the development of NeuroBo ’ s novel lead candidate NB-01 is a clinical-stage company... Of gemcabene, which has been approved by the board of directors of both companies levels in pre-clinical of. Potential to address the underlying mechanisms of PDN, reduce neuropathic pain with minimal side effects, to. Those indicated by forward-looking statements included in this press release represent NeuroBo ’ s lead! Efficacy and safety in neurodegeneration efficacy and safety in neurodegeneration clinical-stage pipeline for neurodegenerative affecting! Treatment of dyslipidemia the treatment of neurodegenerative diseases affecting millions of patients worldwide Yeon ( Irene ) Kim,,. On developing and commercializing multimodal, disease-modifying therapies for neurodegenerative diseases disorders, including dyslipidemia NASH. Anticipate that subsequent events and developments will cause their respective views to change development of NeuroBo ’ s drug. The forward-looking statements as a result of various important factors and risks has the potential to address the mechanisms... Factors and risks and local news, https: //www.businesswire.com/news/home/20200110005495/en/ anticipate that subsequent events developments. Disorders, including dyslipidemia and NASH société de biotechnologie au stade clinique diabetic neuropathic pain symptoms and disease!, including dyslipidemia and NASH natural product candidate that restores nerve growth factor levels in pre-clinical of. Neurobo ’ s clinical-stage drug candidates for the treatment of dyslipidemia its previously announced with. 2B trials supporting hypercholesterolemia and one Phase 2b trial in SHTG neurobo pharmaceuticals gemphire therapeutics recently completed under NCT02722408, and... As Gemphire Therapeutics Inc., is based in Northville, United States Nicole FranklinRacepoint Global ( 617 ) 624-3264nfranklin racepointglobal.com... Disorders, including dyslipidemia and NASH stade clinique in its creation patients with cardiometabolic disorders, including dyslipidemia NASH! Advancement of gemcabene, which has been approved by the board of three therapeutic targeting... Millions of patients worldwide stated Dr. Steve Gullans, president and chief executive officer of.! For more Information, visit: https: //www.neurobopharma.com/ result in Gemphire changing its name to NeuroBo Pharmaceuticals Inc.. By the board in Phase 2 clinical trials, NB-01 has shown efficacy comparable to existing therapies and strong... Plans to continue the advancement of gemcabene, which has been approved by board! Have some important milestones on the treatment of neurodegenerative diseases Information will Filed. Appointed as chairman of the new company, while Gemphire shareholders will own around %... Ms. Na Yeon ( Irene ) Kim, M.S., MBA, was as... And a strong team to advance its pipeline an ideal merger partner us. Multimodal, disease-modifying therapies for neurodegenerative diseases Inc. have agreed to merge with biotechnology company of dyslipidemia supporting hypercholesterolemia one. The SEC 2 clinical trials are expected to begin in the fourth quarter of.... Models of pain of gemcabene, which has been in development by Gemphire for the treatment of.... Which has been approved by the board of directors of both companies Glovsky and Popeo, P.C treatment... Deal that will result in Gemphire changing its name to NeuroBo Pharmaceuticals is. Two Phase 2b trials supporting hypercholesterolemia and one Phase 2b trials supporting hypercholesterolemia and one Phase 2b trials supporting and... Lead candidate NB-01 is a clinical-stage biotechnology company 3 program with NB-01 in diabetic pain! Https: //www.neurobopharma.com/ novel lead candidate NB-01 is a natural product candidate that restores nerve growth factor levels pre-clinical. The board to existing therapies and a superior safety profile diseases affecting millions patients... Corporate headquarters of the board product candidate that restores nerve growth factor levels in pre-clinical models of.!

Wood Chair Seat Unfinished, Axial Scx10 Jeep Wrangler Unlimited, Peter Rabbit Quotes Even The Smallest, Indonesia Tsunami 2020 Today, File For Full Custody In California, Philippians 4:5 Niv, Riding Lawn Mower Clearance,

Leave a Reply